Citation

Michos ED, Mitchell CM, Miller ER, Sternberg AL, Juraschek SP, Schrack JA, Szanton SL, Walston JD, Kalyani RR, Plante TB, Christenson RH, Shade D, Tonascia J, Roth DL, Appel LJ, Appel LJ, Cronin N, Juraschek SP, McClure S, Mitchell CM, Plante TB, Kalyani RR, Roth DL, Schrack JA, Szanton SL, Urbanek J, Walston J, Baksh S, Blackford AL, Chattopadhyay S, Dodge J, Ewing C, Jackson R, Lears A, Meinert C, Shade D, Smith M, Sternberg AL, Tonascia J, Van Natta ML, Wagoner A, Michos ED, Bowers P, Coresh J, Crunkleton T, Dick B, Evans R, Godwin M, Hammann L, Hawks D, Horning K, Minotti M, Myers M, Raley L, Reid C, Spikes A, Stouffer R, Weicht K, Miller ER, Carey B, Charleston J, DeRoche-Brown N, Gayles D, Glenn-Smith I, Johnson D, Johnson M, Keyes E, McArthur K, Santiago D, Sapun C, Sneed V, Thomas L, Christenson RH, Duh SH, Rebuck H, Rosen CJ, Cook T, Duncan P, Hansen K, Kenny A, Shapses S, Hannah J, Romashkan S, Davis CD, Guralnik JM, Gallagher JC. Contemp. Clin. Trials 2018; 73: 111-122.

Affiliation

Creighton University School of Medicine, United States.

Copyright

(Copyright © 2018, Elsevier Publishing)

DOI

10.1016/j.cct.2018.08.004

PMID

30138718

Abstract

Prior evidence suggests that vitamin D supplementation may reduce fall risk, but existing data are inconsistent and insufficient to guide policy. We designed a two-stage Bayesian response-adaptive dose-finding and seamless confirmatory randomized trial of vitamin D supplementation to prevent falls. Up to 1200 community-dwelling persons, aged ≥70 years, of predominantly white and African-American race, with serum 25(OH)D concentrations of 10-29 ng/mL and at elevated fall risk, will be randomized to one of four vitamin D3 (cholecalciferol) supplement doses: 200 (control), 1000, 2000, or 4000 IU/day and treated for up to 2 years. Stage 1 is designed to identify the best of the non-control doses for fall prevention. If a best dose is selected, Stage 2 will start seamlessly, with enrollees assigned to control or the best dose in Stage 1 continuing on that dose unchanged, enrollees assigned to the two non-control, non-best doses in Stage 1 switched to the best dose, and new enrollees randomly assigned 1:1 to control or the best dose. In Stage 2, we will compare the control dose group to the best dose group to potentially confirm the efficacy of that dose for fall prevention. The primary outcome measure in both stages is time to first fall or death, whichever comes first. Falls are ascertained from calendars, scheduled interviews, or interim self-reports. Secondary outcome measures include time to each component of the composite primary outcome and gait speed. Additional outcomes include the Short Physical Performance Battery score, physical activity level (assessed by accelerometry), and frailty score. CLINICAL TRIAL REGISTRATION: NCT02166333.

Copyright © 2018. Published by Elsevier Inc.

Language: en

Keywords

Adaptive Design; Aging; Falls; Randomized Trial; Vitamin D